Numeta G16%E emulsion for infusion
Authorisation PA2299/030/001 · Baxter Holding B.V.
- Licence holder
- Baxter Holding B.V. (all products →)
- Active substances
- Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic acid, Glycine, Histidine, Isoleucine, Leucine, Lysine monohydrate, Methionine, Ornithine hydrochloride, Phenylalanine, Proline, Serine, Taurine, Threonine, Tryptophan, Tyrosine, Valine, Sodium chloride, Potassium acetate, Calcium chloride dihydrate, Magnesium acetate tetrahydrate, Sodium glycerophosphate, hydrated, Glucose monohydrate, Refined olive oil + refined soybean oil
- Dosage form
- Emulsion for infusion
- Route of administration
- Intravenous use
- ATC codes
- B05BA, B05BA10
- First authorised
- 05/12/2011
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Fixed combination application (Article 10b of Directive No 2001/83/EC)
Alanine: supply and approvals
19 authorised products on the HPRA list contain Alanine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- 6 supply notices, e.g. Aminosteril N-Hepa 8% (22 Apr 2026 to 31 Dec 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Arginine: supply and approvals
18 authorised products on the HPRA list contain Arginine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- 6 supply notices, e.g. Aminosteril N-Hepa 8% (22 Apr 2026 to 31 Dec 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Aspartic Acid: supply and approvals
15 authorised products on the HPRA list contain Aspartic Acid. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 14 years (since 5 December 2011). The HPRA list marks it as marketed in Ireland.
Other medicines with Alanine in Ireland
32 other products on the HPRA list contain Alanine, from 4 licence holders; 20 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Finomel Emulsion for Infusion | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Finomel Peri Emulsion for Infusion | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Kabiven Peripheral emulsion for infusion | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
| Kabiven emulsion for infusion | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
| Numeta G13%E Preterm emulsion for infusion | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Numeta G19%E emulsion for infusion | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Omeflex peri emulsion for infusion | B. Braun Melsungen AG | National authorisation (PA) | Marketed |
| Omeflex plus emulsion for infusion | B. Braun Melsungen AG | National authorisation (PA) | Marketed |
| Omeflex special emulsion for infusion | B. Braun Melsungen AG | National authorisation (PA) | Marketed |
| Omeflex special without electrolytes emulsion for infusion | B. Braun Melsungen AG | National authorisation (PA) | Marketed |
| SmofKabiven Peripheral, emulsion for infusion | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
| SmofKabiven extra Nitrogen, emulsion for infusion | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
Other medicines with Arginine in Ireland
28 other products on the HPRA list contain Arginine, from 4 licence holders; 20 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Finomel Emulsion for Infusion | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Finomel Peri Emulsion for Infusion | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Kabiven Peripheral emulsion for infusion | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
| Kabiven emulsion for infusion | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
| Numeta G13%E Preterm emulsion for infusion | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Numeta G19%E emulsion for infusion | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Omeflex peri emulsion for infusion | B. Braun Melsungen AG | National authorisation (PA) | Marketed |
| Omeflex plus emulsion for infusion | B. Braun Melsungen AG | National authorisation (PA) | Marketed |
| Omeflex special emulsion for infusion | B. Braun Melsungen AG | National authorisation (PA) | Marketed |
| Omeflex special without electrolytes emulsion for infusion | B. Braun Melsungen AG | National authorisation (PA) | Marketed |
| SmofKabiven Peripheral, emulsion for infusion | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
| SmofKabiven extra Nitrogen, emulsion for infusion | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
Other substances in ATC group B05BA
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 65 other active substances share the group B05BA with this product:
Sodium acetate trihydrate (14) · Potassium chloride (13) · Lysine acetate (11) · Lysine hydrochloride (10) · Fish oil, rich in omega-3 acids (10) · Glucose anhydrous (10) · Soya bean oil, refined (9) · Triglycerides, medium chain (9) · Olive oil, refined (8) · Glucose (8) · Magnesium chloride hexahydrate (6) · Sodium hydroxide (6) · Histidine hydrochloride monohydrate (6) · Lysine (6) · L-leucine (4) · L-phenylalanine (4) · L-methionine (4) · L-isoleucine (4) · L-valine (4) · L-histidine (4) · and 45 more
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Baxter Holding B.V. holds 73 products on the HPRA list, with 111 different active substances; 62 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.